IFNγ has an essential effect on macrophage activation and clearly a pathogenic role in MAS considering that Emapalumab, which is an anti-IFNγ monoclonal antibody, has been recently approved for the treatment of hemophagocytic lymphohistiocytosis [47–49]. This evidence concerns the gene IFNG and hemophagocytic syndrome.